Translational Science

Translational science connects mechanism and nonclinical models to what you expect in patients: exposure-response relationships, pharmacodynamic markers, patient selection hypotheses, and early clinical endpoints that can actually test the biology. It is the discipline that keeps first-in-human and Phase 2 designs from floating free of the data you already paid for in the lab. Without translation, teams often discover too late that the clinical design cannot confirm or refute the core hypothesis.

Viltis supports translational planning for small molecules, biologics, and complex modalities where model relevance and biomarker strategy decide how much risk you carry into the clinic. We help integrate in vitro, in vivo, and emerging clinical observations into dose rationale, sampling schedules, and go/no-go criteria. The output is practical: clearer protocols, better questions for investigators, and fewer surprises when PK/PD does not match the slide model. We also help teams state assumptions openly so governance decisions are made with eyes open.

Translational work also includes saying no. Not every animal finding maps to humans, and not every biomarker is ready for protocol use. We help teams retire weak translational bets early and concentrate clinical sampling and assay spend on measures that can change a dose decision or a cohort definition. That restraint is often what keeps early trials interpretable.

Translational activities we often support

• Mechanism and model relevance assessment
• Exposure-response and dose rationale support
• Biomarker and PD endpoint strategy
• Integration of nonclinical and early clinical data
• FIH and early-phase design input
• Cross-functional translation workshops
• Documentation for regulatory and clinical teams

Translation works when it changes a protocol or a decision, not when it produces another conceptual framework slide. We stay close to the data your program actually has and help the team say clearly what is known, what is assumed, and what the next study must prove. That clarity shortens debates between discovery, clinical, and regulatory and keeps early development honest about uncertainty. If early clinical data already conflict with the nonclinical story, we help re-frame the hypothesis and the next protocol before more patients are enrolled on outdated assumptions.